Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

被引：0
|
作者：
Makharadze, T. [1 ]
Gogishvili, M. [2 ]
Melkadze, T. [3 ]
Baramidze, A. [3 ]
Giorgadze, D. [4 ]
Penkov, K. D. [5 ]
Laktionov, K. [6 ]
Nemsadze, G. [7 ]
Nechaeva, M. [8 ]
Rozhkova, I. [9 ]
Kalinka, E. [10 ]
Li, S. [11 ]
Li, Y. [11 ]
Kaul, M. [11 ]
Pouliot, J-F. [11 ]
Seebach, F. [11 ]
Lowy, I. [11 ]
Gullo, G. [11 ]
Rietschel, P. [11 ]
机构：
[1] High Technol Hosp Medctr, Batumi, Georgia
[2] High Technol Med Ctr, Tbilisi, Georgia
[3] Acad F Todua Med Ctr, Tbilisi, Georgia
[4] David Tvildiani Med Univ, Tbilisi, Georgia
[5] Private Med Inst Euromedserv, St Petersburg, Russia
[6] Minist Hlth Russian Federat, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia
[7] Inst Clin Oncol, Tbilisi, Georgia
[8] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia
[9] Kaluga Reg Clin Oncol Dispensary, Kaluga, Russia
[10] Polish Mothers Mem Hosp Res Inst, Lodz, Poland
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5O
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [31] Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial
    Ho, G. F.
    Ozguroglu, M.
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Kulyaba, Y.
    Dvorkin, M.
    Zyuhal, K.
    Scheusan, R. I.
    Li, S.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1570 - S1571
  • [32] Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
    Ozguroglu, M.
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Ho, G. F.
    Kulyaba, Y.
    Dvorkin, M.
    Zyuhal, K.
    Scheusan, R. I.
    Li, S.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1421 - S1421
  • [33] Nivolumab plus chemotherapy for non-small cell lung cancer
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (02): : 81 - 81
  • [34] Amivantamab Plus Chemotherapy in Non-Small Cell Lung Cancer
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (06):
  • [35] OVERALL SURVIVAL RESULTS OF NON-SMALL CELL LUNG-CANCER PATIENTS - CHEMOTHERAPY ALONE VERSUS CHEMOTHERAPY WITH COMBINED IMMUNOMODULATION
    SERDENGECTI, S
    BUYUKUNAL, E
    MOLINAS, N
    DEMIRELLI, FH
    BERKARDA, N
    EYUBOGLU, H
    DERMAN, U
    BERKARDA, B
    CHEMIOTERAPIA, 1988, 7 (02): : 122 - 126
  • [36] S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial
    Pisters, K.
    Vallieres, E.
    Bunn, P. A., Jr.
    Crowley, J.
    Chansky, K.
    Ginsberg, R.
    Gandara, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Sequential versus standard chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase III randomised trial
    Paesmans, M.
    Berghmans, T.
    Lafitte, J. J.
    Lecomte, J.
    Alexopoulos, C. G.
    Van Cutsem, O.
    Giner, V.
    Efremidis, A.
    Scherpereel, A.
    Sculier, J. P.
    LUNG CANCER, 2006, 52 : S26 - S27
  • [38] Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis
    Kalinka-Warzocha, E.
    Gogishvili, M.
    Makharadze, T.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nechaeva, M.
    Rozhkova, I.
    He, X.
    Quek, R.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S983 - S984
  • [39] EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the secondline treatment of advanced non-small cell lung cancer (NSCLC)
    Shim, B. Y.
    Lee, S.
    de Castro Carpeno, J.
    Chiu, C-H.
    Cobo, M.
    Kim, H. R.
    Ryu, J. S.
    Tarruella, M. M.
    Summers, Y.
    Thomas, C. A.
    Xu, Y.
    Lowy, I.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S820 - S820
  • [40] Non-small cell Lung Cancer: Neoadjuvant Chemotherapy versus adjuvant Chemotherapy
    Lorenz, Judith
    ZENTRALBLATT FUR CHIRURGIE, 2019, 144 (03): : 215 - +
12345